bortezomib in kidney transplantationbortezomib在肾移植.pdfVIP

Hindawi Publishing Corporation Journal of Transplantation Volume 2010, Article ID 698594, 6 pages doi:10.1155/2010/698594 Review Article Bortezomib in Kidney Transplantation Rajeev Raghavan,1, 2 Abdallah Jeroudi,1 Katafan Achkar,3, 4 A. Osama Gaber,5 Samir J. Patel,6 and Abdul Abdellatif1, 2 1 Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA 2 Division of Nephrology, Baylor College of Medicine, Houston, TX 77030, USA 3 Department of Medicine, The Kidney Institute and The Methodist Hospital, Houston, TX 77030, USA 4 Division of Nephrology, The Kidney Institute and The Methodist Hospital, Houston, TX 77030, USA 5 Department of Surgery, The Methodist Hospital, Weill Cornell University, Houston, TX 77030, USA 6 Department of Pharmacy, The Methodist Hospital, Weill Cornell University, Houston, TX 77030, USA Correspondence should be addressed to Abdul Abdellatif, abdula@ Received 27 July 2010; Accepted 9 September 2010 Academic Editor: H. Kreis Copyright © 2010 Rajeev Raghavan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Although current therapies for pretransplant desensitization and treatment of antibody-mediated rejection (AMR) have had some success, they do not specifically deplete plasma cells that produce antihuman leukocyte antigen (HLA) antibodies. Bortezomib, a proteasome inhibitor approved for the treatment of multiple myeloma (a plasma cell neoplasm), induces plasma cell apoptosis. In this paper we review the current body of literature regarding the use of this biological agent in the field of transplantation. Although li